These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15970124)

  • 41. Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough.
    Yehudai L; Feit F
    J Interv Cardiol; 2006 Oct; 19(5):464-9. PubMed ID: 17020572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjunctive pharmacologic therapy in percutaneous coronary intervention: part I antiplatelet therapy.
    Kim SJ; Giugliano RP; Jang IK
    Coron Artery Dis; 2011 Mar; 22(1):100-12. PubMed ID: 20926950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
    Akkus NI; Rajpal S; Agnani S
    J Invasive Cardiol; 2012 Feb; 24(2):76-8. PubMed ID: 22294539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
    Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New approaches to the pharmacological treatment of angina.
    Denktas AE; Bayes-Genis A; Schwartz RS
    Curr Opin Pharmacol; 2001 Apr; 1(2):151-8. PubMed ID: 11714089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).
    Saucedo JF; Aude W; Pacheco R; Thorn B; Matin Z; Husain K; Garza L
    Am J Cardiol; 2005 Jun; 95(12):1453-6. PubMed ID: 15950569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
    Danchin N; Aïssaoui N
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):325-30. PubMed ID: 20714797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bleeding complications during percutaneous coronary intervention.
    Bhatt DL
    J Invasive Cardiol; 2004 Jul; 16(7 Suppl):24S-29S. PubMed ID: 23573568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
    Meyer BJ
    Schweiz Med Wochenschr; 1996 Nov; 126(46):1961-9. PubMed ID: 8984604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
    Steinhubl S; Berger P
    Am Heart J; 2003 Jun; 145(6):971-8. PubMed ID: 12796751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
    Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heparin dose during percutaneous coronary intervention: how low dare we go?
    Niccoli G; Banning AP
    Heart; 2002 Oct; 88(4):331-4. PubMed ID: 12231583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study).
    Dangas G; Lasic Z; Mehran R; Cox D; Ghali MG; Henry TD; Teirstein PS; Stella JF; Browne KF; Lewis SA; Knopf W; Leon MB; Moses JW; Stone GW
    Am J Cardiol; 2005 Sep; 96(5):659-63. PubMed ID: 16125490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
    Mehta SR;
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolving management of ST-segment elevation myocardial infarction: update on recent data.
    Cannon CP
    Am J Cardiol; 2006 Dec; 98(12A):10Q-21Q. PubMed ID: 17169625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel.
    Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A
    Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.